Cargando…
Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand
Targeted alpha therapy is an emerging strategy for the treatment of disseminated cancer. [(223)Ra]RaCl(2) is the only clinically approved alpha particle-emitting drug, and it is used to treat castrate-resistant prostate cancer bone metastases, to which [(223)Ra]Ra(2+) localizes. To specifically dire...
Autores principales: | Abou, Diane S., Thiele, Nikki A., Gutsche, Nicholas T., Villmer, Alexandria, Zhang, Hanwen, Woods, Joshua J., Baidoo, Kwamena E., Escorcia, Freddy E., Wilson, Justin J., Thorek, Daniel L. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179459/ https://www.ncbi.nlm.nih.gov/pubmed/34163647 http://dx.doi.org/10.1039/d0sc06867e |
Ejemplares similares
-
Prostate Cancer Theranostics - An Overview
por: Abou, Diane, et al.
Publicado: (2020) -
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma
por: Bell, Meghan M., et al.
Publicado: (2020) -
ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors
por: Escorcia, Freddy E., et al.
Publicado: (2020) -
(225)Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
por: King, A. Paden, et al.
Publicado: (2023) -
Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling
por: Tsionou, Maria Iris, et al.
Publicado: (2017)